Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 25;17(1):563.
doi: 10.1186/s13063-016-1675-8.

Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM

Mohamed Bouattour  1 , Olivier Soubrane  2 , Armand de Gramont  3 , Sandrine Faivre  4
Affiliations

Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM

Mohamed Bouattour et al. Trials. .

Abstract

Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical practice and future research.

Trial registration: ClinicalTrials.gov: NCT00692770 . Registered 5 June 2008. This study has been completed.

Keywords: Antiangiogenic agents; Clinical trials; Hepatectomy; Local ablation.

PubMed Disclaimer

References

    1. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–54. doi: 10.1016/S1470-2045(15)00198-9. - DOI - PubMed
    1. Pantel K, Cote RJ, Fodstad Ø. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999;91:1113–24. doi: 10.1093/jnci/91.13.1113. - DOI - PubMed
    1. Mountzios G, Pentheroudakis G, Carmeliet P. Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster. Pharmacol Ther. 2014;141:117–24. doi: 10.1016/j.pharmthera.2013.09.003. - DOI - PubMed
    1. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–109. doi: 10.1158/0008-5472.CAN-04-1443. - DOI - PubMed
    1. de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol. 2015;12:197–212. doi: 10.1038/nrclinonc.2014.202. - DOI - PubMed

MeSH terms

Associated data